Background {#Sec1}
==========

Chronic pain is defined as pain lasting more than 3 months and can be seen as a disease in its own right \[[@CR1]\]. The prevalence rates of chronic pain are in the range of 27% in European countries \[[@CR2]\], equivalent to international estimates \[[@CR3], [@CR4]\]. This condition is associated with a high disease burden in terms of personal suffering, low quality of life, and high economic costs, and is considered as a major health care problem worldwide \[[@CR5], [@CR6]\]. According to the Global Burden of Disease Study of 2017 \[[@CR7]\], over the 28-year period from 1990 to 2017, low back pain, headache disorders, and depressive disorders have prevailed as three of the top four leading causes of years lived with disability worldwide.

The biopsychosocial approach is regarded as the gold standard in the treatment of chronic pain \[[@CR8], [@CR9]\]. Psychological interventions, such as the acceptance and commitment therapy (ACT), constitute a core component within this approach. ACT aims to increase openness to difficult experiences such as pain, as well as awareness of behavioral options, and to facilitate behavior change processes that are in line with personal life values in the presence of these experiences \[[@CR10], [@CR11]\]. Various methods of delivering ACT have been shown to be effective in treating chronic pain: either as individual face-to-face intervention (e.g., \[[@CR12], [@CR13]\]), group-delivered face-to-face (e.g., \[[@CR14]--[@CR23]\]), self-help books \[[@CR24], [@CR25]\], or Internet-based delivery \[[@CR26]--[@CR30]\]. The British Pain Society recommends ACT in the treatment of chronic pain \[[@CR31]\] and although ACT has also been implemented in public care for patients with chronic pain in some countries, considerable barriers to implement psychological interventions have been observed \[[@CR32]\].

The effectiveness of ACT for improving pain-related outcomes has been supported in several (non-Cochrane) reviews, with the consistent conclusion that ACT appears to be equally effective as traditional cognitive behavior therapy \[[@CR33]--[@CR36]\]. The latest meta-analysis found small to large effect sizes for measures of functioning, anxiety, and depression (SMD = − 0.45, − 0.57 and − 0.84, respectively) \[[@CR35]\]. No treatment effects were observed with regard to the outcomes for quality of life and pain intensity \[[@CR35]\]. This evidence-base suggests that the effects of ACT, as with most treatments for chronic pain, need to be improved. One way to do so is to broaden our understanding of which patient characteristics and conditions as well as mode of treatment delivery (e.g., internet-based or face-to-face) are associated with treatment effects and which are not \[[@CR32], [@CR35], [@CR37], [@CR38]\]. Hence, examining effect moderators of chronic pain treatment would greatly facilitate patient tailored interventions and constitute a crucial step forward in the management of chronic pain.

A few systematic reviews have already investigated this issue. There is one review focusing on ACT and mindfulness-based approaches by Gilpin and colleagues \[[@CR39]\], and reviews on other psychological and non-psychological pain approaches \[[@CR40]--[@CR42]\], and with regard to certain specified aspects, such as fear-avoidance beliefs \[[@CR43]\]. In the review by Gilpin and colleagues \[[@CR39]\], some evidence was found that higher psychological distress or history of depression is associated with greater improvements in mindfulness-based interventions. Equivalent to an earlier review on behavioral and cognitive-behavioral interventions \[[@CR42]\], this review found that relationships between demographic variables and treatment outcome were inconsistent and not significant in most cases \[[@CR39]\]. In the review on self-management programs in musculoskeletal pain \[[@CR41]\], one study showed that higher levels of depression at baseline predicted poorer physical functioning at 6 months \[[@CR44]\]. In patients with low back pain, high fear-avoidance beliefs were associated with more pain and/or disability and lower likelihood to return to work \[[@CR43]\]. In general, most of the trials reviewed did not include subgroup analyses and most of the trials with these analyses lacked the power to find reliable treatment effects for specific subgroups. Hence, the evidence-base of treatment moderators is inconsistent. Also, due to the high heterogeneity of the included studies, meta-analyses (MA) of aggregated data (AD, hereinafter referred as AD-MA) were not conducted in the above reviews. Consequently, the current state of scientific knowledge on treatment predictors and moderators is fragmented, inconclusive, and therefore difficult to interpret.

A meta-analysis of individual participant data (IPD, hereinafter referred as IPD-MA) may therefore be a reliable method to overcome high heterogeneity across trials. This not only refers to methodological aspects (e.g., choice of predictor, moderator, and outcome variables, length of follow-up) but also to aspects of the study population, such as gender or a specific pain condition. By using IPD, standardization of analyses and reporting of results across studies, direct derivation of outcomes can be facilitated, independent of how these were reported \[[@CR45]\]. IPD also increases the power to detect differential treatment effects between individual participants, allowing for additional examination of who is most likely to respond with a wider range of statistical analyses. Given these reasons and the advantages over AD-MAs, the IPD-MA has been described as the gold standard of systematic reviews \[[@CR46]\].

Therefore, the present project aims to conduct an IPD-MA and an AD-MA to systematically review studies on ACT for chronic pain (ACT-CP-MA) in order to provide comprehensive insights into the effects of ACT for chronic pain. In detail, ACT-CP-MA aimsTo provide an updated AD-MA on the effects of ACT on pain interference and other key outcomes in individuals with chronic pain.To conduct an IPD-MA to evaluate the effects of ACT on pain interference and other key outcomes of individuals with chronic pain.To identifyindividual-related effect modifiers (predictive markers): socio-demographic and pain-related characteristics, ACT-related processes,treatment-related effect modifiers: traditional one-to-one face-to-face ACT, group-delivered face-to-face ACT, or internet intervention, number of sessions, andstudy-related effect modifiers (recruitment strategy, quality of assessment, control groups)factors that moderate treatment effects of ACT in chronic pain in the included randomized controlled trials (RCTs). For these analyses based on IPD, we will derive various factors from ACT theory and research on chronic pain and formulate specific research questions \[[@CR47]--[@CR51]\].

Due to the complexity of this research field, this study protocol describes the general aims of ACT-CP-MA. The specific research questions for the moderator analyses will be presented and reported separately in respective future publications.

Methods {#Sec2}
=======

We will conduct ACT-CP-MA in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement (PRISMA \[[@CR52]\], see PRISMA-P checklist in Additional file [1](#MOESM1){ref-type="media"}) and the extension of PRISMA for IPD-MAs \[[@CR53]\]. Studies will be selected according to the PICOS criteria \[[@CR54]\] outlined in the following and summarized in Table [1](#Tab1){ref-type="table"}.Table 1PICOS elements of the study inclusion criteriaParticipantsAdult persons (≥ 18 years) with chronic, non-malignant pain (duration \> 3 months)InterventionPain-specific ACT, different modes of deliverye.g.• Face-to-face individual• Face-to-face group• Self-help book with/without guidance• Self-help internet intervention with/without guidanceComparator• Active chronic pain-specific (ACT or non-ACT) treatment• Wait-list• Treatment as usual• Attention control• Psychological placebo• No treatmentOutcomes• Pain specific: interference and intensity• Emotional functioning: depression and anxiety• Health-related quality of life• Participants' rating of overall improvement• ACT specific: pain acceptance, psychological flexibilityStudy designRandomized controlled trials with ethics approval*ACT* acceptance and commitment therapy

Participants {#Sec3}
------------

The population of interest consists of adult persons (≥ 18 years) with chronic (duration [\>]{.ul} 3 months), non-malignant pain. If a study has included both adolescents and young adults over the age of 18 years, this study will be excluded since it can be assumed that the treatment settings for adults and children/adolescents/young adults can be very heterogenous. Inclusion of primary studies will not be further limited to specific clinical subgroups in order to increase power and the ability to inspect the role of individual and study differences.

Intervention {#Sec4}
------------

In this review, we will exclusively focus on ACT-based interventions. Consistent with a recent review on ACT for chronic pain \[[@CR35]\], studies will be included only if the intervention explicitly uses the full ACT model. In accordance with a recent review on predictors and moderators in ACT and mindfulness-based approaches \[[@CR39]\], the high heterogeneity in the theoretical base of treatment and therapeutic mechanisms can cause differences in individual responsiveness and may explain inconsistencies between studies. Consequently, we will exclude studies with purely mindfulness-based interventions. All ACT interventions regardless of their mode of delivery will be included in the review (e.g., face-to-face, individual, group, self-help book, internet intervention).

Comparator(s) {#Sec5}
-------------

We will include trials if the comparison group received either an active treatment for chronic pain (ACT or non-ACT) or a control condition, i.e., treatment as usual, psychological placebo, attention control condition, waitlist control, or no treatment.

Outcomes {#Sec6}
--------

Our selection of outcomes is based on recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT; \[[@CR50], [@CR51], [@CR55]\]) as well as on theoretically relevant aspects of ACT \[[@CR39], [@CR56]--[@CR62]\].

### Pain-specific outcomes {#Sec7}

IMMPACT recommends the use of the Multidimensional Pain Inventory (MPI; \[[@CR63]\]) or interference scale of the Brief Pain Inventory (BPI; \[[@CR64]\]) as validated self-report questionnaires for pain interference. In case of multiple outcome measures for pain interference, we will favor the MPI due to the higher number of items (nine in the MPI versus even in the BPI) and given that it is the most frequently used outcome measure across studies. If none of these questionnaires were used in the studies, comparable validated self-report questionnaires, such as the pain disability index (PDI; \[[@CR65]\]) will be used (randomly in case of multiple measure). The scores of different questionnaires will be standardized to allow all measures of pain to be modeled together.

The following secondary outcome measures must be assessed by standardized measures:Pain intensity (numeric or visual analogue scales)Depression (e.g., Patient Health Questionnaire (PHQ-9 \[[@CR66]\]) or The Hospital Anxiety Depression Scale (HADS \[[@CR67]\]))Anxiety (e.g., HADS \[[@CR67]\], Generalized Anxiety Disorder-7 scale \[[@CR68]\])Health-related quality of life (HrQol; e.g., short form 12-item survey (SF-12 \[[@CR69]\]), Assessment of Quality of Life (AQoL-8D \[[@CR70]\]), or the EuroQol (EQ-5D \[[@CR71]\]))Participants' rating of overall improvement (e.g., Patient Global Impression of Change (PGIC \[[@CR72]\]))ACT-related variables (e.g., psychological flexibility the Acceptance and Action Questionnaire-II (AAQ-II \[[@CR73]\]), the Chronic Pain Acceptance Questionnaire (CPAQ \[[@CR74]\]), or the Committed Action Questionnaire (CAQ \[[@CR60]\]))

Predictors and moderators of treatment outcome {#Sec8}
----------------------------------------------

We differentiate between individual predictors, treatment-related moderators, and study-level moderators for treatment outcome. Individual predictors for treatment outcome are variables assessed at baseline before the start of the treatment. The following factors are defined as potential individual predictors for treatment outcome in this study: socio-demographic factors (age, gender, employment status, level of education, relationship status, comorbid somatic/psychiatric conditions), pain-related factors (pain duration, baseline pain interference, and intensity), and baseline ACT-related factors (e.g., pain acceptance). We identified these factors to be potential predictors of treatment effect from single studies and reviews with inconsistent findings \[[@CR32], [@CR35], [@CR38]--[@CR41], [@CR75]--[@CR81]\]. Treatment-related factors are the proportion of intended number of sessions attended.

Study-level moderators for treatment outcome include intervention characteristics (i.e., mode of intervention delivery, number of modules/sessions, level of guidance) and study characteristics (i.e., recruitment setting, such as open recruitment through self-referral, or recruitment in primary, secondary or tertiary care). We will also collect information on adverse events and adherence to the treatment as reflected by the percentage of completed modules in each study-specific treatment. We will summarize these data on a descriptive level, given that these aspects are not expected to be reported in all identified studies and as adherence can only be observed in the interventions groups.

Study design {#Sec9}
------------

Randomized controlled trials (RCTs) of any length of follow-up and any setting will be included if reported. We will not apply any exclusion based on publication status, date, or type. We will only use data from studies that received ethics approval and that are published in English.

Study identification and selection {#Sec10}
----------------------------------

To minimize publication bias, we will search for published and unpublished trials. For the published trials, we will search for RCTs of ACT for chronic pain in the following databases using medical subject headings (MeSH): (1) Cochrane Central Register of Controlled Trials (CENTRAL), (2) MEDLINE, (3) EMBASE, and (4) PsycINFO. We will use RCT filters for MEDLINE and EMBASE and applied adaptations of these to the other databases. Two reviewers (JL and WS) developed the MEDLINE strategy. The search strategy for the literature search is included in Additional file [2](#MOESM2){ref-type="media"}.

Additionally, we will search in the International Standard Randomized Controlled Trial Number register (ISRCTN), WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials. Gov, and PROSPERO and examine reference lists of all references of included trials and reviews to identify other potentially relevant studies. Further, we will contact all corresponding authors of included trials and asked about other RCTs, published or unpublished, which might be eligible for the review. These strategies are important in order to find eligible "gray literature" (i.e., unpublished trials, trials, and trials reported as meeting abstracts, book chapters, and letters \[[@CR82]\]).

Two reviewers (JL and WS) will independently select relevant studies for inclusion. First, we will examine a list of titles and abstracts. If title and abstract contain sufficient information to determine exclusion, we will exclude the respective article. For all remaining articles, we will retrieve and review the full text independently. In addition, we will review all other potentially relevant articles identified by checking the reference lists or personal communications. If there are discrepancies between reviewers at any stage of the process, we will consult a third reviewer (LM).

Data collection {#Sec11}
---------------

We will initially contact the corresponding author of all identified trials to invite them to participate in ACT-CP-MA and to share their raw data (see Additional file [3](#MOESM3){ref-type="media"} for contact letter, a modified version of \[[@CR83]\]). This invitation contains a short introduction to ACT-CP-MA, including the aim, inclusion criteria, and outcomes as well as a short description of the ACT-CP-MA procedures. We will offer PIs who have shared their data to become a co-author in the result publications. They are also invited to become active collaborators within the project. If we cannot contact the corresponding author, we will email all co-authors listed. If we fail to receive a response to our initial email invitation, we will send reminders after two and if, necessary, after 4 weeks. If the study investigators are still not responding or unwilling to contribute their study data, we will send a final note inquiring why they are unable to participate. If there is no response after 4 weeks, the trial will be excluded as "unavailable."

In order to increase the feasibility of the IPD-MA, we will provide regular e-mail updates to keep the collaborative group up to date and involved. On an online collaboration platform ([trello.com](http://trello.com)), we will present all procedures during the acquisition of the data and the analysis and their respective deadlines so that the procedures will be transparent to all collaborators.

We will seek from all relevant trials data for all participants at all assessment times, including those excluded from the investigators' own analyses. In order to minimize the amount of work for study authors, we will accept databases in all formats. Before transferring the data, we will ask the investigators to anonymize the data and to use a password-protected encryption. Once we have received the original data file, we will archive the original data as backup and transfer the IPD to a converted and combined overall dataset with standardized variables, the ACT-CP-IPD database. For data harmonization, we will apply the procedures described in Buffart et al. \[[@CR84]\]. We will discuss any inconsistencies with the original authors and make corrections when necessary.

For the AD-MA, a standardized data extraction form has been developed and will be piloted, based on the template of the Cochrane good practice data extraction form (Version 4, April 2014, see Additional file [4](#MOESM4){ref-type="media"}) to extract data from the selected studies.

Assessment of risk of bias in included studies {#Sec12}
----------------------------------------------

Two reviewers (JL and WS) will independently assess risk of bias using the Cochrane Risk of Bias assessment tool, focusing on the evaluation of sequence generation, allocation concealment, blinding (participants, personnel, and outcome assessors), incomplete data, selective outcome reporting, and assessing other biases \[[@CR85]\]. Additionally, the researchers (JL and WS) will assess the evidence profiles for each of the identified outcomes based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to reviewing evidence \[[@CR86]--[@CR88]\]. In case of disagreement between the reviewers, discussions or consultation of a third reviewer (MD) will take place. For the trials that were conducted by JL or WS, MD will assess the risk of bias instead of JL or WS, respectively. If needed, a statistician (SN or LC) will be consulted regarding judgments relating to statistical analyses.

Statistical analysis {#Sec13}
--------------------

### Individual participant data meta-analyses {#Sec14}

We will perform analyses according to current expert recommendations for individual participant data meta-analysis \[[@CR45], [@CR89]\]. By using mixed-effects models, we will apply the one-stage approach IPD-MA based on the combination of all data in a single meta-analysis \[[@CR89], [@CR90]\]. In order to consider clustering effects from study to study, we will apply a two-level hierarchical structure: the participants within each trial as level 1 and the trial as level 2. We will perform all analyses on a modified intention-to-treat (ITT) basis using a statistical interpolation strategy for missing data within the mixed-effects model. For this strategy, we will include all randomized participants with outcome data.

Using mixed-effects models, we will examine treatment effects on the specified outcomes. With regard to potential treatment moderators on the outcomes, we will examine interactions between the intervention and the above-mentioned individual predictors, treatment-related moderators, and study-level moderators. For data management and harmonization, SPSS will be used as most datasets will be available in SPSS format. Analyses will be conducted using R (R Foundation for Statistical Computing, \[[@CR91]\]) which offers a wide variety of basic to advanced statistical and graphical techniques.

### Aggregate data meta-analyses {#Sec15}

For those studies where IPD were not provided, a sensitivity analysis exploring the estimated treatment effect with AD will be conducted. To estimate the treatment effect of ACT compared to different control groups, we will calculate the effect sizes (Hedges' *g*) \[[@CR92]\], which will be pooled using a random-effects meta-analysis. We will test for statistical heterogeneity using the Chi2 test (significance level: 0.1) and *I*^2^ statistic on the basis of the Cochrane Handbook \[[@CR93]\] recommendations. To examine publication bias, we will visually inspect the funnel plot, by using the trim and fill procedure and Egger's test of funnel plot asymmetry \[[@CR94], [@CR95]\]. A sensitivity analysis will also be conducted excluding studies with high risk of bias.

This AD-MA will exclusively examine treatment effects on the specified outcomes without investigating potential treatment moderators or predictors. This decision is based on the lack of studies investigating these variables in ACT and mindfulness-based treatments for chronic pain as documented in a recent meta-analysis \[[@CR39]\]. Further, for variables measured at the individual level, the IPD-MA will have considerably greater power to investigate this research question in comparison to an AD-MA.

The results with regard to the treatment effects of both meta-analyses will be compared: By doing this, we will analyze and discuss potential differences between studies included in the IPD-MA and those not included.

Discussion {#Sec16}
==========

ACT-CP-MA will use a thoroughly defined methodology and provide an updated review on the effect of ACT for chronic pain. It will be the first study that comprehensively examines data with an explorative study approach including important potential predictor and moderators of treatment effects. Therefore, it can overcome predefined hypotheses that were applied in each included primary study and allows for an overview of factors that may be crucial to treatment effects observed in ACT for chronic pain.

The central strength of this study lies in the methodological approach which will use an IPD-MA of randomized controlled studies on ACT for chronic pain based on an extensive search of multiple databases, journals, references, and citations. We will deal with a wide array of outcomes based on theory and experts' recommendations as well as with individual-based predictors and treatment-related moderators of treatment effects. Using the same systematic procedures, harmonization of variables and analyses on these variables across multiple studies, we will provide a consistent evidence synthesis across all variables. Results of this review will be published in international medical and psychological journals and presented at national and international conference meetings following the PRISMA statement \[[@CR52], [@CR53]\].

Limitations {#Sec17}
-----------

We will possibly face some difficulties in obtaining original data from all of the identified trials. These difficulties may result in a bias to the IPD-MA \[[@CR45]\]. Therefore, we will additionally conduct an AD-MA with all identified studies. This AD will provide a basis for comparisons between the AD-MA and IPD-MA. Furthermore, we will increase the exchange in the field of research on ACT and chronic pain in order to build a collaborative network to facilitate the exchange of data.

Conclusions {#Sec18}
===========

In ACT-CP-MA, we will review RCTs of ACT for chronic pain and bring together relevant evidence. We will discuss the findings with regard to future directions of research on ACT for chronic pain as well as implications for health care services to help people make well-informed decisions. The information on different treatment predictors and moderators may help clinicians match patients most likely to benefit from ACT with this treatment approach in the sense of personalized medicine. This will also allow conclusions on which characteristics of individuals would best benefit from which form of intervention (face to face, internet-based, group-based, individual). Thereby, treatment costs may be better controlled by allocating treatment resources where they are likely to be most effective \[[@CR42]\]. Therefore, the results of this review may provide a basis for treatment guidelines for chronic pain patients with respect to the provision of ACT and its type of delivery. The findings of this study will help researchers to refine ACT-based interventions for chronic pain. In the development phase, knowledge of user characteristics that are linked to greater improvements can be used to enhance the efficacy of ACT through greater targeting of treatment toward those characteristics.

The IPD-database of this project is conceptualized as a basis for other MAs to come in the future. As not all research questions might be answerable due to the unavailability of the current evidence, this project is designed as a long-term project in which we will continuously update the IPD-database and subsequently provide more in-depth analyses on the effectiveness of ACT in chronic pain patients. Different researchers within the collaborative network of this project can investigate different specific research questions. For example, more knowledge on treatment processes within ACT and patient characteristics can be an essential step forward to improve treatment effects for chronic pain \[[@CR96]--[@CR105]\]. The collaborative structure of this project will also stimulate scientific exchange between experts in the field which might generate ideas for methods to improve future trials or treatment development.

Additional files
================

 {#Sec19}

Additional file 1:ACT-CP-MA PRISMA-P checklist. (DOCX 31 kb) Additional file 2:ACT-CP-MA bibliographic database searches. (DOCX 20 kb) Additional file 3:ACT Pain IPD invitation letter. (DOCX 26 kb) Additional file 4:ACT-CP-MA data extraction form. (DOC 187 kb)
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